Pharmaceutical composition for preventing or treating bone diseases

Abstract

A composition according to an embodiment of the present disclosure includes a N-phenyl-methylsulfonamido-acetamide compound represented by Formula 1, useful as a pharmaceutical compound to inhibit osteoclast differentiation and/or formation. The compound exhibits excellent prophylactic or therapeutic effects on various bone diseases including periodontitis and the like. Examples of the N-phenyl-methylsulfonamido-acetamide compound represented by Formula 1 are wherein the compound represented by Formula 1 above is selected from the group consisting of: 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-(phenylthio)phenyl)acetamide; 2-(N-(5-chloro-2-methoxyphenyl)methylsulfonamido)-N-(2-(phenylthio)phenyl)acetamide; N-([1,1′-biphenyl]-2-yl)-2-(N-(3-acetylphenyl)methylsulfonamido)acetamide); 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-(phenylamino)phenyl)acetamide; 2-(N-(3-acetylphenyl)methylsulfonamido)-N-(2-phenoxyphenyl)acetamide; and N2-(3,5-dimethylphenyl)-N2-(methylsulfonyl)-N-[2-(phenylthio)phenyl]alanineamide. A method for treating a bone disease caused by hyperdifferentiation of osteoclasts according to an embodiment of the present disclosure includes administering to a subject in need thereof the composition.

Dependencies are inferred from the claim text.